Two‐year safety and effectiveness of the platinum chromium everolimus‐eluting stent for the treatment of small vessels and longer lesions
PS Teirstein, IT Meredith, RL Feldman… - Catheterization and …, 2015 - Wiley Online Library
Objectives To report 1‐and 2‐year clinical outcomes of patients receiving platinum
chromium everolimus‐eluting stents (PtCr‐EES) in the prospective, single‐arm PLATINUM …
chromium everolimus‐eluting stents (PtCr‐EES) in the prospective, single‐arm PLATINUM …
Cost‐effectiveness of percutaneous coronary intervention with cobalt‐chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta …
N Ferko, G Ferrante, JT Hasegawa… - Catheterization and …, 2017 - Wiley Online Library
Background Second‐generation drug eluting stents (DES) may reduce costs and improve
clinical outcomes compared to first‐generation DES with improved cost‐effectiveness when …
clinical outcomes compared to first‐generation DES with improved cost‐effectiveness when …
The intersection of prescription drugs and medical devices: the evaluation and funding challenges of two categories of emerging health technologies
C Rodrigues, R Fu, T Ghose, E Yurga… - International Journal of …, 2025 - cambridge.org
Health technology assessments (HTAs) are policy analysis frameworks contributing to the
approval, reimbursement, and rollout of biotechnology and pharmaceuticals. New …
approval, reimbursement, and rollout of biotechnology and pharmaceuticals. New …
Cost‐effectiveness analysis of biodegradable polymer versus durable polymer drug‐eluting stents incorporating real‐world evidence
M Teng, YJ Zhao, AL Khoo… - Cardiovascular …, 2018 - Wiley Online Library
Aim Compared with second‐generation durable polymer drug‐eluting stents (DP‐DES), the
cost‐effectiveness of biodegradable polymer drug‐eluting stents (BP‐DES) remains unclear …
cost‐effectiveness of biodegradable polymer drug‐eluting stents (BP‐DES) remains unclear …